Citadel Advisors’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-70,500
| Closed | -$1.67M | – | 15734 |
|
|
2023
Q4 | $1.67M | Sell |
70,500
-103,500
| -59% | -$1.84M | ﹤0.01% | 5700 |
|
|
2023
Q3 | $2.59M | Buy |
174,000
+169,400
| +3,683% | +$2.25M | ﹤0.01% | 4751 |
|
|
2023
Q2 | $50.4K | Sell |
4,600
-17,000
| -79% | -$158K | ﹤0.01% | 11796 |
|
|
2023
Q1 | $188K | Buy |
21,600
+4,700
| +28% | +$37.6K | ﹤0.01% | 10284 |
|
|
2022
Q4 | $106K | Buy |
16,900
+6,200
| +58% | +$23.6K | ﹤0.01% | 11135 |
|
|
2022
Q3 | $37K | Sell |
10,700
-100
| -0.9% | -$359 | ﹤0.01% | 11801 |
|
|
2022
Q2 | $32K | Sell |
10,800
-600
| -5% | -$1.43K | ﹤0.01% | 12188 |
|
|
2022
Q1 | $35K | Sell |
11,400
-401,300
| -97% | -$1.26M | ﹤0.01% | 13023 |
|
|
2021
Q4 | $1.4M | Buy |
412,700
+4,800
| +1% | +$18.2K | ﹤0.01% | 7061 |
|
|
2021
Q3 | $1.49M | Sell |
407,900
-24,000
| -6% | -$94.6K | ﹤0.01% | 7095 |
|
|
2021
Q2 | $1.88M | Sell |
431,900
-6,700
| -2% | -$29.7K | ﹤0.01% | 6764 |
|
|
2021
Q1 | $1.99M | Buy |
438,600
+18,700
| +4% | +$101K | ﹤0.01% | 6397 |
|
|
2020
Q4 | $2.41M | Buy |
419,900
+386,500
| +1,157% | +$2.93M | ﹤0.01% | 4971 |
|
|
2020
Q3 | $242K | Buy |
33,400
+14,400
| +76% | +$77K | ﹤0.01% | 8501 |
|
|
2020
Q2 | $66K | Buy |
+19,000
| New | +$54.8K | ﹤0.01% | 9190 |
|
|
2020
Q1 | – | Sell |
-13,600
| Closed | -$27K | – | 10356 |
|
|
2019
Q4 | $27K | Buy |
+13,600
| New | +$51.1K | ﹤0.01% | 8897 |
|
|
2019
Q3 | – | Sell |
-121,900
| Closed | -$873K | – | 9901 |
|
|
2019
Q2 | $873K | Buy |
+121,900
| New | +$1.38M | ﹤0.01% | 5914 |
|
Other funds holding CBAY
Citadel Advisors's CBAY Position: Q1 2024 in Review
Citadel Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 330,234 shares — an estimated $7.8M sold.
Citadel Advisors first reported a position in CBAY in Q1 2015 and held it in 31 quarters. The position peaked at $37.3M in Q1 2019. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Citadel Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Citadel Advisors sold 330,234 Cymabay Therapeutics shares in Q1 2024, an estimated $7.8M.
- Citadel Advisors first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 31 quarters.
- Citadel Advisors's Cymabay Therapeutics position peaked at $37.3M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.